Navigation Links
Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference

ALISO VIEJO, Calif., Oct. 12, 2011 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that pseudobulbar affect (PBA) prevalence data from stroke survivors will be highlighted at the 88th Annual Meeting of the American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine in Atlanta, GA.

Following are details about the data presentation at ACRM/ASNR Progress in Rehabilitation Research:

Title: Pseudobulbar Affect in Stroke: A National Stroke Association Survey
Program Number: 0025
Presentation Date/Time: Thursday, October 13, 2011 5:00-7:00 p.m. EST & Friday October 14, 2011 4:30-6:45 p.m. EST

About PBA

Patients suffering from existing neurological disease or brain injury may also suffer the added burden of pseudobulbar affect, or PBA. PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of crying and/or laughing. PBA episodes typically occur out of proportion or incongruent to the patient's underlying emotional state. PBA outbursts result from a "short circuit" in the brain caused by another neurologic condition-such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), stroke, or traumatic brain injury. PBA can have a debilitating impact on the lives of patients, caregivers and loved ones. For more information about PBA, please visit

About Avanir Pharmaceuticals, Inc.

Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit

AVANIR™ is a trademark owned by Avanir Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners

©2011 Avanir Pharmaceuticals, Inc. All Rights Reserved.

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals to Participate in Two Investor Conferences
2. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
3. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
4. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
5. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
6. Avanir Pharmaceuticals to Present at Two Investor Conferences in August
7. Avanir Pharmaceuticals Provides Update on European Regulatory Filing for NUEDEXTA
8. Avanir Pharmaceuticals Announces Paragraph IV ANDA Filing for NUEDEXTA
9. Avanir Pharmaceuticals Reports Fiscal 2011 Second Quarter Results
10. Avanir Pharmaceuticals Announces Appointment of Elona Kogan, Esq. as Vice President of Legal Affairs
11. Avanir Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference
Post Your Comments:
(Date:10/13/2015)... FRANCISCO , October 13, 2015 ... to reach USD 26.8 billion by 2022, according to ... and respiratory devices, owing to their capability to resolve ... to witness a substantial growth. --> anesthesia ... USD 26.8 billion by 2022, according to a new ...
(Date:10/13/2015)... SHANGHAI , Oct. 13, 2015 ... R&D capability and technology platform company serving the ... that it has launched a mobile version of ... allow researchers to access oncology models and data ... clients anywhere and at any time to identify ...
(Date:10/13/2015)... --  Micell Technologies , Inc. today announced four-year clinical ... its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System ... the 27th Annual Transcatheter Cardiovascular Therapeutics ( TCT ) ... October 11-15. TCT is the world,s largest educational meeting ... to optimize vessel healing in patients with coronary artery ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... Altec Products, Inc., the leader in ... Dynamics AXUG, GPUG and NAVUG Summits to take place the week of October ... user conferences designed and led by users to provide attendees with a unique ...
(Date:10/13/2015)... ... , ... Symposium Chairman, Dr. Rod J. Rohrich is pleased to announce that ... March 2nd and 3rd, 2016. The annual meeting, along with the Dallas Rhinoplasty ... around the world. , Key topics at this year's event will include discussions on ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... IBM software products, introduced a new company, RightSensor™ LLC, an Internet of Things ... capability. RightSensor™ provides a fully-managed approach for customers requiring sensor hardware for ...
(Date:10/13/2015)... ... 2015 , ... In an age where the cost of energy is rising, ... foot than in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 ... eight percent. , According to Facilities Management Administrative Director Dieter Reichmann, this is ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology ... today a significant contract that will provide its award-winning private messaging solution to ... the growing success of its Relay program, IBX Wire™, which now has over ...
Breaking Medicine News(10 mins):